Drug firm Zydus Cadila on Monday said it has received positive results from phase 2(b) studies of Desidustat in COVID-19 patients conducted in Mexico. In June 2020, Zydus Cadila had received approval from Mexico's regulatory authority Cofepris to test one of its lead research candidates Desidustat in the management of COVID-19.Drug firm Zydus Cadila on Monday said it has received positive results from phase 2(b) studies of Desidustat in COVID-19 patients conducted in Mexico. In June 2020, Zydus Cadila had received approval from Mexico's regulatory authority Cofepris to test one of its lead research candidates Desidustat in the management of COVID-19. January 25, 2021 at 11:31AM https://ift.tt/366bcUv
No comments:
Post a Comment